A5043547211- Rheumatoid Arthritis Research and Therapies
- Spondyloarthritis Studies and Treatments
- Autoimmune and Inflammatory Disorders Research
- Vasculitis and related conditions
- Renal Diseases and Glomerulopathies
- Monoclonal and Polyclonal Antibodies Research
- Biosimilars and Bioanalytical Methods
- Otitis Media and Relapsing Polychondritis
- Sarcoidosis and Beryllium Toxicity Research
- Osteomyelitis and Bone Disorders Research
- Urticaria and Related Conditions
- Toxin Mechanisms and Immunotoxins
- Fibromyalgia and Chronic Fatigue Syndrome Research
Autonomous Healthcare
2024
Khanty-Mansiysk State Medical Academy
2021-2023
York District Hospital
2017-2019
The Russian biotechnological company «BIOCAD» has designed a chimeric monoclonal antibody against CD20 (BCD-020, Acellbia®) that is biosimilar of rituximab (RTM; MabThera®, F. Hoffmann-La Roche Ltd., Switzerland). In recent years, there been evidence RTM can be used at lower doses than those given in the standard recommendations and instructions for use this drug. This serves as basis BCD-020-4/ALTERRA (ALTErnative Rituximab regimen Rheumatoid Arthritis) trial, objective which was to...
In 2013, Russia registered officially the indications for use of monoclonal antibodies to B-lymphocytes (rituximab, RTM) in systemic vasculitides associated with antineutrophil cytoplasmic (ANCA-SV). This communication presents preliminary results Russian register RTM application autoimmune diseases (NORMA) that has included 50 patients ANCA-SV treated 14 cities Federation. Twenty-five (50%) received repeated courses RTM. demonstrated a high efficacy and good profile treatment safety...
Objective: to evaluate the effect of golimumab (GLM) on clinical, functional, and instrumental manifestations coxitis in ankylosing spondylitis (AS). Subjects methods. The non-interventional prospective multicenter cohort study GO-COX conducted medical centers Russian Federation enrolled 39 patients with AS (meeting modified New York criteria) BASRI-hip score 0–2, who were prescribed GLM as first biologic agent at a dose 50 mg per month. patient's health status was assessed using Bath...
The efficacy and safety of levilimab (LVL) in patients with active rheumatoid arthritis (RA) has been confirmed controlled clinical trials. This article presents the results a preliminary analysis non-interventional observational study LVL RA patients. Objective: to evaluate treatment real-world practice. Materials methods. HELIOS is retrospective-prospective, multicenter, retention rate therapy Patients received medical care, including LVL, according routine practice for Russian...
The hip joint is the most commonly affected non-axial in ankylosing spondylitis (AS). Data on effects of tumor necrosis factor-α inhibitors (TNFi) AS patients with coxitis are limited. aim this study was evaluation treated TNFi golimumab real-world settings.This a prospective non-interventional cohort study. A total 39 newly prescribed were enrolled and followed for up to 24 months. data collected included BASFI, BASMI, ASDAS-CRP, BASDAI indices. BASRI-hip X-ray score assessed at baseline,...
<h3>Background</h3> Rituximab (RTX) therapy is a treatment option in patients with antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis. <h3>Objectives</h3> Analysis of safety and efficacy RTX ANCA-associated vasculitis treated fourteen Russian clinical centers. <h3>Methods</h3> In 2011, Nasonova V.A. Research Institute Rheumatology Association Rheumatologists Russia created the NORMA project, multicenter study whose objective to gather information concerning use adult systemic...
Background: Coxitis (hip joint inflammation) in AS is associated with worse BASFI scores due to hip involvement and more severe axial disease [1]. Radiological index of BASRI-hip, US MRI findings may be used for evaluation impairment [2, 3, 4]. Number studies on coxitis patients treated biologics was limited at time this study initiation. Objectives: To evaluate clinical changes measured by BASFI, BASMI, BASDAI, ASDAS-CRP radiological (BASRI-hip, [STIR- T1-weighted sequences], US) after 12...